Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1976 1
1991 1
1992 3
1993 3
1994 5
1995 2
1996 6
1997 6
1998 7
1999 10
2000 7
2001 13
2002 14
2003 11
2004 9
2005 15
2006 11
2007 9
2008 8
2009 9
2010 16
2011 7
2012 15
2013 6
2014 10
2015 6
2016 6
2017 11
2018 14
2019 16
2020 11
2021 16
2022 11
2023 11
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

281 results

Results by year

Filters applied: . Clear all
Page 1
The Role of Magnesium in Pathophysiology and Migraine Treatment.
Dolati S, Rikhtegar R, Mehdizadeh A, Yousefi M. Dolati S, et al. Biol Trace Elem Res. 2020 Aug;196(2):375-383. doi: 10.1007/s12011-019-01931-z. Epub 2019 Nov 5. Biol Trace Elem Res. 2020. PMID: 31691193 Review.
This neurological disorder is characterized by having pain in head and other various symptoms such as nausea, emesis, photophobia, phonophobia, and sometimes visual sensory disorders. Magnesium (Mg) is a necessary ion for human body and has a crucial role in health and lif …
This neurological disorder is characterized by having pain in head and other various symptoms such as nausea, emesis, photophobia, phonop …
Sex and Gender Considerations in Episodic Migraine.
Ahmad SR, Rosendale N. Ahmad SR, et al. Curr Pain Headache Rep. 2022 Jul;26(7):505-516. doi: 10.1007/s11916-022-01052-8. Epub 2022 Jun 9. Curr Pain Headache Rep. 2022. PMID: 35679008 Free PMC article. Review.
In part 1, we examine migraine epidemiology in the context of sex and gender, differences in symptomatology, and the influence of sex hormones on migraine pathophysiology (including CGRP). In part 2, we focus on practical clinical considerations for sex and gender in episo …
In part 1, we examine migraine epidemiology in the context of sex and gender, differences in symptomatology, and the influence of sex hormon …
Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society.
Oskoui M, Pringsheim T, Holler-Managan Y, Potrebic S, Billinghurst L, Gloss D, Hershey AD, Licking N, Sowell M, Victorio MC, Gersz EM, Leininger E, Zanitsch H, Yonker M, Mack K. Oskoui M, et al. Neurology. 2019 Sep 10;93(11):487-499. doi: 10.1212/WNL.0000000000008095. Epub 2019 Aug 14. Neurology. 2019. PMID: 31413171 Review.
No acute treatments were effective for migraine-related nausea or vomiting; some triptans were effective for migraine-related phonophobia and photophobia. RECOMMENDATIONS: Recommendations for the treatment of acute migraine in children and adolescents focus on the importan …
No acute treatments were effective for migraine-related nausea or vomiting; some triptans were effective for migraine-related phonophobia …
Role of CGRP in Migraine.
Edvinsson L. Edvinsson L. Handb Exp Pharmacol. 2019;255:121-130. doi: 10.1007/164_2018_201. Handb Exp Pharmacol. 2019. PMID: 30725283
It is characterized by episodic, often disabling headache, photophobia and phonophobia, autonomic symptoms (nausea and vomiting), and in a subgroup an aura in the beginning of the attack. ...The neurobiology of CGRP signaling is briefly summarized together with key clin …
It is characterized by episodic, often disabling headache, photophobia and phonophobia, autonomic symptoms (nausea and vomiting), and …
Ubrogepant for the Treatment of Migraine.
Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, Szegedi A. Dodick DW, et al. N Engl J Med. 2019 Dec 5;381(23):2230-2241. doi: 10.1056/NEJMoa1813049. N Engl J Med. 2019. PMID: 31800988 Clinical Trial.
BACKGROUND: Ubrogepant is an oral, small-molecule calcitonin gene-related peptide receptor antagonist for acute migraine treatment. METHODS: We conducted a randomized trial to evaluate the efficacy, safety, and side-effect profile of ubrogepant. ...Secondary end poi …
BACKGROUND: Ubrogepant is an oral, small-molecule calcitonin gene-related peptide receptor antagonist for acute migraine treatment. METHODS: …
Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans.
de Vries T, Villalón CM, MaassenVanDenBrink A. de Vries T, et al. Pharmacol Ther. 2020 Jul;211:107528. doi: 10.1016/j.pharmthera.2020.107528. Epub 2020 Mar 12. Pharmacol Ther. 2020. PMID: 32173558 Review.
Migraine is a highly disabling neurovascular disorder characterized by a severe headache (associated with nausea, photophobia and/or phonophobia), and trigeminovascular system activation involving the release of calcitonin-gene related peptide (CGRP). ...Of these drugs tar …
Migraine is a highly disabling neurovascular disorder characterized by a severe headache (associated with nausea, photophobia and/or phon …
Efficacy and safety of intranasal agents for the acute treatment of migraine: a systematic review and network meta-analysis.
Li G, Duan S, Zhu T, Ren Z, Xia H, Wang Z, Liu L, Liu Z. Li G, et al. J Headache Pain. 2023 Sep 18;24(1):129. doi: 10.1186/s10194-023-01662-6. J Headache Pain. 2023. PMID: 37723470 Free PMC article. Review.
METHODS: The Cochrane Register of Controlled Trials, Embase, and PubMed were searched from inception to 15 August 2023. Randomized controlled trials (RCTs) using intranasal agents (no restrictions on dose, formulation, dosing regimen or timing of the first dose) to treat a …
METHODS: The Cochrane Register of Controlled Trials, Embase, and PubMed were searched from inception to 15 August 2023. Randomized co …
Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study.
Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB; COL MIG-301 Study Group. Kuca B, et al. Neurology. 2018 Dec 11;91(24):e2222-e2232. doi: 10.1212/WNL.0000000000006641. Epub 2018 Nov 16. Neurology. 2018. PMID: 30446595 Free PMC article. Clinical Trial.
OBJECTIVE: To assess the efficacy and safety of lasmiditan in the acute treatment of migraine. METHODS: Adult patients with migraine were randomized (1:1:1) to a double-blind dose of oral lasmiditan 200 mg, lasmiditan 100 mg, or placebo and were asked to treat their next m …
OBJECTIVE: To assess the efficacy and safety of lasmiditan in the acute treatment of migraine. METHODS: Adult patients with migraine were …
Naratriptan.
Massiou H. Massiou H. Curr Med Res Opin. 2001;17 Suppl 1:s51-3. doi: 10.1185/0300799039117016. Curr Med Res Opin. 2001. PMID: 12463278 Review.
It was found significantly superior to placebo on headache relief and pain free at 2 and 4 hours, and in relieving nausea, photophobia and phonophobia. It also has a good within-patient consistency, and a low recurrence rate. ...
It was found significantly superior to placebo on headache relief and pain free at 2 and 4 hours, and in relieving nausea, photophobia and …
Lasmiditan: First Approval.
Lamb YN. Lamb YN. Drugs. 2019 Dec;79(18):1989-1996. doi: 10.1007/s40265-019-01225-7. Drugs. 2019. PMID: 31749059 Review.
Approval was based on positive results from two pivotal phase III trials, in which lasmiditan significantly improved the proportions of patients achieving freedom from headache pain and freedom from the most bothersome symptom (photophobia, phonophobia or nausea), relative …
Approval was based on positive results from two pivotal phase III trials, in which lasmiditan significantly improved the proportions of pati …
281 results